Background: Multiple animal models have previously been utilized to investigate anterior fusion techniques, but a mouse model has yet to be developed. The purpose of this study was to develop murine anterior interbody and posterolateral fusion techniques. Methods: Mice underwent either anterior interbody or posterolateral spinal fusion. A protocol was developed for both procedures, including a description of the relevant anatomy. Samples were subjected to micro-computed tomography to assess fusion success and underwent biomechanical testing with use of 4-point bending. Lastly, samples were fixed and embedded for histologic evaluation. Results: Surgical techniques for anterior interbody and posterolateral fusion were developed. The fusion rate was 83.3% in the anterior interbody model and 100% in the posterolateral model. Compared with a control, the posterolateral model exhibited a greater elastic modulus. Histologic analysis demonstrated endochondral ossification between bridging segments, further confirming the fusion efficacy in both models. Conclusions: The murine anterior interbody and posterolateral fusion models are efficacious and provide an ideal platform for studying the molecular and cellular mechanisms mediating spinal fusion. Clinical Relevance: Given the extensive genetic tools available in murine disease models, use of fusion models such as ours can enable determination of the underlying genetic pathways involved in spinal fusion.
S1. The relative expression of KLK3/PSA. S2. Kaplan-Meier analysis of prostate cancer outcome was obtained from GEPIA tool. S3. LNCaP cells with the indicated treatments were seeded in the upper chamber of the Boyden's transwell chamber. S4. LNCaP cells with the indicated treatments were seeded in the upper chamber of the Boyden's transwell chamber which were coated with 1:20 diluted Matrigel. S5. LNCaP cells with the indicated treatments were seeded in the upper chamber of the Boyden's transwell chamber. S6. Snapshots form the AR ChIP-seq showing AR binding to the ARBS. S7. Screenshot from the AR ChIP-seq shows marked reduction in AR binding to the ARBS located at ~ 30kb from the NDRG1 after LINC00844 knock-down in LNCaP cells. S8. LNCaP cells with the indicated treatments were seeded in the upper chamber of the Boyden's transwell chamber. S9. LNCaP cells we co-transfected with the with the indicated siRNA and plasmids and seeded in the upper chamber of the Boyden's transwell chamber. S10. LNCaP cells we co-transfected with the with the indicated siRNA and plasmids cells were harvested and the required amount of cells were used for the migration and invasion assay and rest were lysed for western blot analysis.